Reports
Sale
Global Albumin Market Size, Share, Growth, Forecast, Report: By Product: Human Serum Albumin, Recombinant Albumin, Bovine Serum Albumin; By Application: Drug Delivery, Therapeutics, Vaccine Ingredient, Culture Media Diagnostics; By End User: Hospitals & Clinics, Others; Regional Analysis; Supplier Landscape; 2024-2032
Global Albumin Market Outlook
The global albumin market value in 2023 was USD 5.63 billion and is anticipated to grow at a CAGR of 6.20% during the forecast period of 2024-2032, driven by the growing demand for albumin-based drug formulations across the globe. The global albumin market size is anticipated to reach a value of USD 9.67 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Albumin Market Overview
Albumin is the most abundant plasma protein in adult humans, representing 50% of the total protein content of the plasma. The protein has a half-life of 21 days, with a concentration ranging from 35 to 59 g/L in the blood plasma. Albumin is synthesized by the liver at the rate of 10-15 grams per day. It has approximately 100 variant forms and plays an important role in maintaining the oncotic pressure to prevent the leaking of fluids into the extravascular space.
Albumin plays several physiological roles. It is accountable for maintaining 80% of the colloid osmotic pressure. A decrease in the level of serum albumin causes hypoalbuminemia, which is one of the most prevalent disorders In hospitalized and critically ill patients. Hypoalbuminemia has a prevalence rate of 70% in elderly hospitalized patients. Thus, the rising incidence of hypoalbuminemia is one of the key factors driving the albumin market growth.
The market is further boosted by the rising liver and cardiovascular disorders, which makes individuals prone to a low albumin levels in the body. In addition, the therapeutic and non-therapeutic applications of human serum albumin are propelling the market demand.
Technological Developments Expediating Albumin-Based Drug Delivery System
Albumin has become a popular delivery carrier for hydrophobic drugs due to advancements in nanotechnology. The surge in clinical applications is expected to boost the albumin market share in the forecast period. Owing to its unique chemical structure, albumin allows effective interaction with many drugs and protects them from elimination in vivo. In May 2023 , reverse QTY (rQTY) code was utilized to design amphiphilic human serum albumin (HAS) proteins, which resolved the problem of protein denaturation at the time of drug loading. Additionally, the HAS rQTY variants exhibited superior biological activities like tumor cell-targeting as compared to the denatured HAS nanoparticles. Such technological advancements in the drug development sector are bolstering the demand for albumin in the pharmaceutical industry.
Rise in Funding and Investment to Meet Albumin Market Demand
The pharmacokinetic and pharmacodynamic profile of albumin makes it an effective drug carrier. To exploit its versatility as a protein delivery vehicle, there has been increased funding and investment in the albumin market. In December 2023 , an Indian biopharmaceutical startup, PlasmaGen Biosciences raised around USD 27 million via equity funding to accelerate the growth of blood plasma-based products such as albumin. The company received major financing from Artian Investments (an investment management firm based in the United Kingdom) and other prominent investors.
Another major investment boosting the albumin market value was witnessed when SK Plasma, a South Korean developer of plasma-derived medicine, received USD 50 million from the Indonesia Investment Authority (INA), a government-owned sovereign wealth fund in October 2023. The funds will be used to build a plasma fractionation plant for manufacturing blood products such as albumin and immunoglobulin. Expected to be built by 2025, the facility is projected to process a million liters of raw plasma every year. The growing investments in the albumin market are anticipated to increase the market size in the coming years.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Albumin Market Segmentation
Market Breakup by Product
- Human Serum Albumin
- Recombinant Albumin
- Bovine Serum Albumin
Market Breakup by Application
- Drug Delivery
- Therapeutics
- Vaccine Ingredient
- Culture Media Diagnostics
Market Breakup by End User
- Hospitals & Clinics
- Pharmaceutical & Biotechnology Industry
- Research Institutes
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Albumin Market Regional Analysis
In North America, the market growth of albumin is driven by the rising research and development activities for expanding the clinical applications of human, bovine, and recombinant serum albumin. Technological advancements in protein purification and molecular separation technology are anticipated to boost market growth.
Europe holds a significant albumin market share, owing to the presence of top healthcare companies in the region. Moreover, the rising focus of government on the development of albumin-derived pharmaceuticals is propelling market growth. In June 2023, the health authority in the United Kingdom, the Medicines and Healthcare Products Regulatory Agency (MHRA) lifted the ban on the use of blood plasma from donors of the United Kingdom to derive albumin. The authorization to use UK donor plasma to manufacture albumin treatments is expected to aid in the expansion of the albumin market in the region.
Global Albumin Market: Competitor Landscape
The expansion of manufacturing capacities and capabilities by the leading healthcare companies to accommodate the growing demand for albumin is one of the major market trends. In June 2023, Thermo Fisher Scientific, a biotechnology company based in the United States developed a ‘Biologics Manufacturing Facility’ covering an area of 1.5 million square feet in Switzerland. Thermo Fischer Scientific, along with their strategic partner CSL Limited (a global biotechnology company) will use the facility to produce Idelvion, a next-generation hemophilia product having recombinant albumin as an essential component, among other things. The growing demand for albumin in the development of drugs is expected to increase the albumin market size in the forecast period.
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Albumedix
- Albumin Therapeutics, LLC
- Biotest AG
- CSL
- Grifols, S.A.
- HiMedia Labortatories
- Invitria
- Medxbio Pte Ltd.
- Octapharma AG
- RayBiotech, Inc.
- SeraCare
- Merck KGaA
- Takeda Pharmaceutical Company Limited
- Kedrion S.p.A.
- Aspira
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Albumin Market Overview
3.1 Global Albumin Market Historical Value (2017-2023)
3.2 Global Albumin Market Forecast Value (2024-2032)
4 Global Albumin Market Landscape*
4.1 Global Albumin Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Albumin Product Landscape
4.2.1 Analysis by Product
4.2.2 Analysis by Application
5 Global Albumin Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Albumin Market Segmentation (2017-2032)
6.1 Global Albumin Market (2017-2032) by Product
6.1.1 Market Overview
6.1.2 Human Serum Albumin
6.1.3 Recombinant Albumin
6.1.4 Bovine Serum Albumin
6.2 Global Albumin Market (2017-2032) by Application
6.2.1 Market Overview
6.2.2 Drug Delivery
6.2.3 Therapeutics
6.2.4 Vaccine Ingredient
6.2.5 Culture Media Diagnostics
6.3 Global Albumin Market (2017-2032) by End User
6.3.1 Market Overview
6.3.2 Hospitals & Clinics
6.3.3 Pharmaceutical & Biotechnology Industry
6.3.4 Research Institutes
6.4 Global Albumin Market (2017-2032) by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Albumin Market (2017-2032)
7.1 North America Albumin Market (2017-2032) by Product
7.1.1 Market Overview
7.1.2 Human Serum Albumin
7.1.3 Recombinant Albumin
7.1.4 Bovine Serum Albumin
7.2 North America Albumin Market (2017-2032) by Application
7.2.1 Market Overview
7.2.2 Drug Delivery
7.2.3 Therapeutics
7.2.4 Vaccine Ingredient
7.2.5 Culture Media Diagnostics
7.3 North America Albumin Market (2017-2032) by Country
7.3.1 United States of America
7.3.2 Canada
8 Europe Albumin Market (2017-2032)
8.1 Europe Albumin Market (2017-2032) by Product
8.1.1 Market Overview
8.1.2 Human Serum Albumin
8.1.3 Recombinant Albumin
8.1.4 Bovine Serum Albumin
8.2 Europe Albumin Market (2017-2032) by Application
8.2.1 Market Overview
8.2.2 Drug Delivery
8.2.3 Therapeutics
8.2.4 Vaccine Ingredient
8.2.5 Culture Media Diagnostics
8.3 Europe Albumin Market (2017-2032) by Country
8.3.1 United Kingdom
8.3.2 Germany
8.3.3 France
8.3.4 Italy
8.3.5 Others
9 Asia Pacific Albumin Market (2017-2032)
9.1 Asia Pacific Albumin Market (2017-2032) by Product
9.1.1 Market Overview
9.1.2 Human Serum Albumin
9.1.3 Recombinant Albumin
9.1.4 Bovine Serum Albumin
9.2 Asia Pacific Albumin Market (2017-2032) by Application
9.2.1 Market Overview
9.2.2 Drug Delivery
9.2.3 Therapeutics
9.2.4 Vaccine Ingredient
9.2.5 Culture Media Diagnostics
9.3 Asia Pacific Albumin Market (2017-2032) by Country
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 ASEAN
9.3.5 Australia
9.3.6 Others
10 Latin America Albumin Market (2017-2032)
10.1 Latin America Albumin Market (2017-2032) by Product
10.1.1 Market Overview
10.1.2 Human Serum Albumin
10.1.3 Recombinant Albumin
10.1.4 Bovine Serum Albumin
10.2 Latin America Albumin Market (2017-2032) by Application
10.2.1 Market Overview
10.2.2 Drug Delivery
10.2.3 Therapeutics
10.2.4 Vaccine Ingredient
10.2.5 Culture Media Diagnostics
10.3 Latin America Albumin Market (2017-2032) by Country
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Mexico
10.3.4 Others
11 Middle East and Africa Albumin Market (2017-2032)
11.1 Middle East and Africa Albumin Market (2017-2032) by Product
11.1.1 Market Overview
11.1.2 Drug Delivery
11.1.3 Therapeutics
11.1.4 Vaccine Ingredient
11.1.5 Culture Media Diagnostics
11.2 Middle East and Africa Albumin Market (2017-2032) by Application
11.2.1 Market Overview
11.2.2 Drug Delivery
11.2.3 Therapeutics
11.2.4 Vaccine Ingredient
11.2.5 Culture Media Diagnostics
11.3 Middle East and Africa Albumin Market (2017-2032) by Country
11.3.1 Saudi Arabia
11.3.2 United Arab Emirates
11.3.3 Nigeria
11.3.4 South Africa
11.3.5 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 India CDSCO
12.1.4 Japan PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication Year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by Year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Albumedix
17.1.1 Company Overview
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Albumin Therapeutics, LLC
17.2.1 Company Overview
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Biotest AG
17.3.1 Company Overview
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 CSL
17.4.1 Company Overview
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Grifols, S.A.
17.5.1 Company Overview
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 HiMedia Labortatories
17.6.1 Company Overview
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Invitria
17.7.1 Company Overview
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Medxbio Pte Ltd.
17.8.1 Company Overview
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Octapharma AG
17.9.1 Company Overview
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 RayBiotech, Inc.
17.10.1 Company Overview
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 SeraCare
17.11.1 Company Overview
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Merck KGaA
17.12.1 Company Overview
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Takeda Pharmaceutical Company Limited
17.13.1 Company Overview
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Kedrion S.p.A a
17.14.1 Company Overview
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 Aspira
17.15.1 Company Overview
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
List not exhaustive
18 Global Albumin Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market attained a value of about USD 5.63 billion in 2023 driven by the growing demand for albumin-based drug delivery systems across the globe.
The market is anticipated to grow at a CAGR of 6.20% during the forecast period of 2024-2032, likely to reach a market value of USD 9.67 billion by 2032.
Advancements in nanotechnology for drug development, along with improvements in protein purification and molecular technologies are contributing to the increasing the market demand.
The surge in funding and investments is one of the major trends driving the albumin market. In December 2023, PlasmaGen Biosciences raised around USD 27 million via equity funding to accelerate the growth of its blood plasma-based products including albumin.
Based on the application type, the market is divided into drug delivery, therapeutics, vaccine ingredients, and culture media diagnostics.
The products in the market include human serum albumin, recombinant albumin, and bovine serum albumin.
Major end users in the market include hospitals, clinics, pharmaceutical as well as biotechnology industry, and research institutes.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.
Key players involved in the market are Albumedix, Albumin Therapeutics, LLC, Biotest AG, CSL, Grifols, S.A., HiMedia Labortatories, Invitria, Medxbio Pte Ltd., Octapharma AG, RayBiotech, Inc., SeraCare, Merck KGaA, Takeda Pharmaceutical Company Limited, Kedrion S.p.A., and Aspira.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER